A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) (PTR-01-001)
A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Sponsor: Phoenix Tissue Repair, Inc.
A PHASE1/PHASE2 clinical study on Recessive Dystrophic Epidermolysis Bullosa, this trial is completed. The trial is conducted by Phoenix Tissue Repair, Inc. and has accumulated 9 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Apr 2020 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2020 — Apr 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2019 — Jan 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2018 — Mar 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Phoenix Tissue Repair, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .